S.Biomedics Co., Ltd. (KOSDAQ:304360)

Market Cap	244.31B
Revenue (ttm)	15.59B
Net Income (ttm)	-7.08B
Shares Out	11.86M
EPS (ttm)	-609.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,989
Average Volume	39,451
Open	20,600
Previous Close	20,600
Day's Range	20,200 - 20,900
52-Week Range	16,130 - 40,700
Beta	1.47
RSI	50.36
Earnings Date	Aug 11, 2025

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 52
• Stock Exchange: KOSDAQ
• Ticker Symbol: 304360

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.